Sub menu

 

 

Questions and answers on additional clarification for inclusion criteria in the “Guideline on clinical investigation of medicinal products in the treatment of Parkinson's disease” rev. 2

We have adopted this International Scientific Guideline - EMA/351466/2012

Last updated

About this guideline

Overseas effective date: 21 June 2012

Provided for information: 1 June 2014

Note: To be read in conjunction with the Guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease (EMA/CHMP/330418/2012 rev.2)

Categories: Clinical efficacy and safety | Nervous system

TGA annotations: Nil

  • Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
  • All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

For more information see International scientific guidelines adopted in Australia.

Product types